News | October 26, 2024
Aarti Drugs posts Q2 FY25 consolidated profit at Rs. 35.01 Cr
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Akums Drugs will undertake this development and commercialization in India
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Subscribe To Our Newsletter & Stay Updated
